DK1290013T3 - Apo-A1/All-peptidderivater - Google Patents

Apo-A1/All-peptidderivater

Info

Publication number
DK1290013T3
DK1290013T3 DK01930664T DK01930664T DK1290013T3 DK 1290013 T3 DK1290013 T3 DK 1290013T3 DK 01930664 T DK01930664 T DK 01930664T DK 01930664 T DK01930664 T DK 01930664T DK 1290013 T3 DK1290013 T3 DK 1290013T3
Authority
DK
Denmark
Prior art keywords
apo
amphipathic helix
domain
helix peptide
peptide
Prior art date
Application number
DK01930664T
Other languages
English (en)
Inventor
Tadahiko Kohno
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1290013T3 publication Critical patent/DK1290013T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01930664T 2000-04-21 2001-04-23 Apo-A1/All-peptidderivater DK1290013T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19892000P 2000-04-21 2000-04-21

Publications (1)

Publication Number Publication Date
DK1290013T3 true DK1290013T3 (da) 2006-06-26

Family

ID=22735445

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01930664T DK1290013T3 (da) 2000-04-21 2001-04-23 Apo-A1/All-peptidderivater

Country Status (12)

Country Link
US (1) US6743778B2 (da)
EP (1) EP1290013B1 (da)
JP (1) JP2003530870A (da)
AT (1) ATE319737T1 (da)
AU (2) AU2001257173B2 (da)
CA (1) CA2407083A1 (da)
DE (1) DE60117781T2 (da)
DK (1) DK1290013T3 (da)
ES (1) ES2260219T3 (da)
MX (1) MXPA02010324A (da)
PT (1) PT1290013E (da)
WO (1) WO2001081376A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407086A1 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US8116889B2 (en) * 2002-06-27 2012-02-14 Openpeak Inc. Method, system, and computer program product for managing controlled residential or non-residential environments
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1682584B1 (en) 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
US7579319B2 (en) * 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007103775A2 (en) * 2006-03-03 2007-09-13 Washington University In St. Louis Biomaterials having nanoscale layers and coatings
EP2537526A1 (en) * 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis
CA2982157A1 (en) * 2009-02-16 2010-08-19 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커
CA2979712C (en) 2015-03-25 2024-01-23 The Regents Of The University Of Michigan Nanoparticle compositions for delivery of biomacromolecules
CA3032229A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
CN116322646A (zh) 2020-10-01 2023-06-23 阿比奥尼克斯制药公司 用于治疗眼病的包含基于脂质结合蛋白的复合物的组合物
EP4322746A1 (en) 2021-04-15 2024-02-21 Abionyx Pharma SA Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
CA2249195A1 (en) * 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998009602A2 (en) 1996-09-05 1998-03-12 The Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis
ES2190543T3 (es) 1996-10-08 2003-08-01 Bisys B V U Procedimientos y sistemas que permiten seleccionar peptidos y proteinas que tienen una afinidad especifica respecto a un blanco.
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
GB9815505D0 (en) 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Also Published As

Publication number Publication date
WO2001081376A2 (en) 2001-11-01
MXPA02010324A (es) 2003-04-25
EP1290013B1 (en) 2006-03-08
CA2407083A1 (en) 2001-11-01
ES2260219T3 (es) 2006-11-01
ATE319737T1 (de) 2006-03-15
AU5717301A (en) 2001-11-07
EP1290013A2 (en) 2003-03-12
WO2001081376A3 (en) 2003-01-09
JP2003530870A (ja) 2003-10-21
DE60117781D1 (de) 2006-05-04
DE60117781T2 (de) 2006-11-23
US6743778B2 (en) 2004-06-01
US20030040470A1 (en) 2003-02-27
AU2001257173B2 (en) 2005-09-22
PT1290013E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
DK1290013T3 (da) Apo-A1/All-peptidderivater
WO2001083527A3 (en) Glucagon antagonists
Atoda et al. The primary structure of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin E
EA200201121A1 (ru) Модуляторы рецепторов паратироидного гормона и родственного паратироидному гормону белка
US6319897B1 (en) Peptides which inhibit complement activation
Hackeng et al. Total chemical synthesis of human matrix Gla protein
AU764589B2 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
Choi-Miura et al. Identification of the disulfide bonds in human plasma protein SP-40, 40 (apolipoprotein-J)
McGavin et al. Fibronectin binding determinants of the Staphylococcus aureus fibronectin receptor
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
CA2131389A1 (en) Thrombin receptor antagonists
Himeshima et al. Amino acid sequence of a lectin from the sea cucumber, Stichopus japonicus, and its structural relationship to the C-type animal lectin family
US6469138B1 (en) Thrombospondin receptor binding peptides
WO2001083526A3 (en) Calcitonin-related molecules
CA2451741C (en) Peyers's patch and/or m-celle targeting ligands
WO2007058267A8 (ja) 新規タンパク質及びそれをコードする遺伝子
Shibata et al. Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide
DE69732583D1 (de) Verfahren zur Spaltung eines chimeren Proteins mittels eines 'processing'-Enzyms
DK1913020T3 (da) Immunogene konstrukter
WO1996004926A1 (en) TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ η1 CHAIN
Thurieau et al. Design and synthesis of new linear and cyclic bradykinin antagonists
Badgery-Parker et al. Receptor binding profile of neuropeptide γ and its fragments: Comparison with the nonmammalian peptides carassin and ranakinin at three mammalian tachykinin receptors
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
JP2002534996A5 (da)
WO2005041882A3 (en) Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs